# Yipu Capital

> Yipu Capital is a VC fund backing Biotechnology, Biopharma and Health Care. See 9 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 9
- Last investment: Apr 2026
- Lead investor: 0%
- Last updated: Aug 2026

Yipu Capital is an investment firm

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 44% |
| Biopharma | 2 | 22% |
| Health Care | 2 | 22% |
| Manufacturing | 2 | 22% |
| Semiconductor | 2 | 22% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 4 | 44% |
| Seed | 1 | 11% |
| Angel | 1 | 11% |
| Series A | 1 | 11% |
| Series C | 1 | 11% |

6 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Lawnics Technology | Lawonics is a manufacturer specializing in high-end intelligent garden and power tools. The company focuses on research, development, and production of garden tools and intelligent equipment, providing smart solutions for various garden and life scenarios. It continuously improves product performance and user experience through advancedtechnologies like intelligent drive, precise calibration, and automatic charging. |  | Venture - Series Unknown | Apr 21, 2026 |  |
| Ronovo Surgical | Ronovo Surgical is an emerging medtech company focused on innovating minimally invasive (MIS) and digital surgery. | $28.3M | Series B | Aug 30, 2023 |  |
| Bio-Engine | Bio-Engine is a developer of high-density serum-free suspension culture technology for animal cells. Its main products include HEK293 cell serum-free medium, PK15 cell serum-free medium, etc., which can be applied to antibodies, recombinant proteins, human and livestock. Virus vaccine, cell therapy and other fields. | $43.1M | Series C | May 15, 2023 |  |
| Qixin Micro Semiconductor | Suzhou Qixin Micro Semiconductor Co., Ltd. was established in October 2020. Based on the ARM Cortex M4, M7 and other series of architectures, it will build high-performance and high-reliability system-on-chips for different automotive application scenarios, and develop high-end smart car controller chips. Through the use of self-developed IP,unique multi-core lock-step technologies, and the unique Six Sigma analog circuit design process for automotive-standard chips, a full series of product families covering safety standards ISO26262 ASIL-B to ASIL-D have been designed. The company's products all meet the automotive regulations AEC-Q100, functional safety standard ISO26262 and various automotive regulations reliability tests, and can be widely used in the fields of body, automotive instrumentation, safety, power, battery management and other fields. The company is mainly engaged in the research and development and sales of high-end automotive controller chips. The goal is to fill the gap in the domestic new generation of intelligent networked automotive controller chips, and is committed to becoming a leading manufacturer in the field of automotive and industrial controllers in China. |  | Series B | Jul 07, 2022 |  |
| EVAS Intelligence | EVAS Intelligence is an autonomous driving chip startup. The company was founded by Liu Hui. | $28.3M | Seed | Mar 01, 2022 |  |
| EVAS Intelligence | EVAS Intelligence is an autonomous driving chip startup. The company was founded by Liu Hui. | $31.7M | Angel | Mar 01, 2022 |  |
| LakeShore Biopharma | Yisheng Biopharma is a global, fully integrated biopharmaceutical company engaged in discovering, developing and commercializing innovative biotherapeutics for cancers and infectious diseases using our novel PIKA® immunomodulating technology. PIKA technology augments both innate and adaptive immune responses through the TLR3, RIG-I and MDA5pathways. Products in clinical development include YS-ON-001 for the treatment of advanced solid tumors, YS-HBV-001 hepatitis B vaccine and the PIKA rabies vaccine for accelerated protection against rabies infection. | $130M | Series B | Feb 24, 2021 |  |
| Lepu Bio | Lepu Bio is a biotech company that develops a tumor immunology technology. It has established an industrial platform for target discovery, drug discovery, development, and production. The company's core products, PD-1, PD-L1, oncolytic virus, and multiple ADC products, have entered the clinical stage I-III. |  | Series A | Apr 01, 2020 |  |
| Transcenta | Transcenta is a global biotherapeutic company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacture, focusing on developing innovative antibodies to help more patients. HJB and MabSpace Biosciences merged and created Transcenta. | $100M | Series B | Jan 08, 2020 |  |

9 of 9 investments shown.

## Co-investors
- [Kington Capital](https://shizune.co/investors/profile/kington-capital) — VC Fund, 4 deals together
- [GAC Capital](https://shizune.co/investors/profile/gac-capital) — VC Fund, 3 deals together
- [CTC Capital](https://shizune.co/investors/profile/ctc-capital) — VC Fund, 2 deals together
- Epiphron Capital — VC Fund, 2 deals together
- [Lilly Asia Ventures](https://shizune.co/investors/profile/lilly-asia-ventures) — VC Fund, 2 deals together
- NRL Capital — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Yipu Capital invest in?

Yipu Capital invests primarily in Biotechnology, Biopharma and Health Care startups, most often at Series B and Seed stage. Most of the 9 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Yipu Capital last invest?

The most recent investment recorded for Yipu Capital closed in Apr 2026. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co